Duchenne Muscular Dystrophy Treatment Receives Pediatric Disease Status from FDA
Marathon Pharmaceuticals, a company that develops new medications for rare diseases with a focus on patients who have no treatment options, recently announced that the U.S. Food and Drug Administration (FDA) has issued a rare pediatric disease designation to deflazacort to treat patients with Duchenne Muscular Dystrophy (DMD). Deflazacort is an oxazoline…